Breast cancer (BC) is the most common cancer, with more than 2,290,000 cases and 666,000 deaths each year worldwide [1], and its subtypes are defined as luminal BC, HER2 BC, and triple-negative BC (TNBC), classified according to therapeutic strategy [2,3,4]. This evidence concerns the gene ERBB2 and breast carcinoma.